Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab.

Journal of the National Cancer Institute - 1 May 2026

Maddalena Giulia, van der Pol Ymke, Villarreal Oscar E, Coker Oluwadara, Min Lee Hey, Rivers Zach, Covert Wendy, Diao Stacy, Lonardi Sara, Rogers Jane E, Dasari Arvind, Guinney Justin, Kopetz Scott, Raghav Kanwal

Abstract excerpt

BACKGROUND: Clinical benefit from later lines of therapy in metastatic colorectal cancer (mCRC) is limited. Patient selection for treatment is crucial for optimal risk-benefit evaluation. Codon-specific KRAS mutations have been implicated as predictive biomarkers for efficacy of trifluridine/tipiracil (TAS-102). However, their predictive impact for TAS-102 plus Bevacizumab (TAS-Bev), the new standard of care in...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Codon
Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 41455083
DOI: 10.1093/jnci/djaf385

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab.PMID 41455083Read ↗

Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial.Semantic proximity Read ↗

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.Semantic proximity Read ↗

Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Semantic proximity Read ↗

Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.Semantic proximity Read ↗

Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib.Semantic proximity Read ↗

KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.Semantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.Semantic proximity Read ↗

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.